Literature DB >> 12423798

The expression of genes involved in microcin maturation regulates the production of active microcin E492.

Gino Corsini1, Marcelo Baeza, Octavio Monasterio, Rosalba Lagos.   

Abstract

The production of active microcin E492, a channel-forming bacteriocin, was studied in exponential and stationary phase. The structural gene for this bacteriocin (mceA) is transcribed in exponential as well as in stationary phase, but the active form is produced only during the exponential phase of growth. An inactive form of microcin E492 was purified from the stationary phase. The production of the inactive form correlated with the lack of transcription in the stationary phase of two genes (mceIJ) involved in microcin E492 maturation, consequently behaving as the inactive form purified from mutants in these genes. The inactive form of microcin purified from the stationary phase as well as the inactive form purified from mutants in the maturation genes (mceC, I, J) were unable to compete with the active form when tested using a viability test on sensitive cells. This result strongly suggests that the inactive form of microcin caused by the lack of expression of the maturation genes is impaired at the level of receptor recognition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423798     DOI: 10.1016/s0300-9084(02)01415-3

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  12 in total

1.  Microcin amyloid fibrils A are reservoir of toxic oligomeric species.

Authors:  Mohammad Shahnawaz; Claudio Soto
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

2.  Cooperative uptake of microcin E492 by receptors FepA, Fiu, and Cir and inhibition by the siderophore enterochelin and its dimeric and trimeric hydrolysis products.

Authors:  Erwin Strahsburger; Marcelo Baeza; Octavio Monasterio; Rosalba Lagos
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Microcin e492 amyloid formation is retarded by posttranslational modification.

Authors:  Andrés Marcoleta; Macarena Marín; Gabriela Mercado; José María Valpuesta; Octavio Monasterio; Rosalba Lagos
Journal:  J Bacteriol       Date:  2013-07-08       Impact factor: 3.490

4.  In vitro characterization of salmochelin and enterobactin trilactone hydrolases IroD, IroE, and Fes.

Authors:  Hening Lin; Michael A Fischbach; David R Liu; Christopher T Walsh
Journal:  J Am Chem Soc       Date:  2005-08-10       Impact factor: 15.419

5.  Biosynthetic tailoring of microcin E492m: post-translational modification affords an antibacterial siderophore-peptide conjugate.

Authors:  Elizabeth M Nolan; Michael A Fischbach; Alexander Koglin; Christopher T Walsh
Journal:  J Am Chem Soc       Date:  2007-10-31       Impact factor: 15.419

6.  The production in vivo of microcin E492 with antibacterial activity depends on salmochelin and EntF.

Authors:  Gabriela Mercado; Mario Tello; Macarena Marín; Octavio Monasterio; Rosalba Lagos
Journal:  J Bacteriol       Date:  2008-05-23       Impact factor: 3.490

7.  Insight into siderophore-carrying peptide biosynthesis: enterobactin is a precursor for microcin E492 posttranslational modification.

Authors:  Gaëlle Vassiliadis; Jean Peduzzi; Séverine Zirah; Xavier Thomas; Sylvie Rebuffat; Delphine Destoumieux-Garzón
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 8.  Fold modulating function: bacterial toxins to functional amyloids.

Authors:  Adnan K Syed; Blaise R Boles
Journal:  Front Microbiol       Date:  2014-08-01       Impact factor: 5.640

9.  Prion-like characteristics of the bacterial protein Microcin E492.

Authors:  Mohammad Shahnawaz; Kyung-Won Park; Abhisek Mukherjee; Rodrigo Diaz-Espinoza; Claudio Soto
Journal:  Sci Rep       Date:  2017-03-31       Impact factor: 4.379

10.  Microcin PDI regulation and proteolytic cleavage are unique among known microcins.

Authors:  Zhe Zhao; Lisa H Orfe; Jinxin Liu; Shao-Yeh Lu; Thomas E Besser; Douglas R Call
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.